Low-grade glioma · 4 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Temozolomide monotherapy Variant #02 | — | R 7 358 | 14d | ~39.0 mo | — | ~26 | ~R 129 994 PFS proxy · indirect | 1 |
Carboplatin and Teniposide Variant #01 Partial | — | R 1 338 | 28d | — | — | ~10 | ~R 13 377 indirect | — |
Carboplatin monotherapy Variant #01 | — | R 535 | 21d | ~5.8 mo | ~21.0 mo | ~2 | ~R 1 070 PFS proxy · indirect | 7 |
PCV Variant #02 Partial | — | R 327 | 56d | — | ~159.6 mo | ~12 | ~R 3 919 PFS proxy · indirect | 1 |
4 of 4 regimens shown